A Study of TAK-505 in Adults With Solid Tumors
Malignant Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 151 (planned)
- Started
- May 11, 2026
- Main results expected
- Aug 18, 2030
- Fully finished
- Aug 18, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: From initial dose until 28 days after infusion of the first cohort dose on Cycle 1 Day 1
Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Clinically Significant Laboratory Values and Vital Signs
Measured over: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)
Phase 2 Dose Expansion: Confirmed Overall Response Rate (ORR)
Measured over: Up to end of study (up to approximately 52 months)
Phase 2 Dose Expansion: Number of Participants With TEAEs, Clinically Significant Laboratory Values and Vital Signs
Measured over: From first dose of trial intervention through 30 days after administration of the last dose of trial intervention (up to approximately 52 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07436728 · record last updated 2026-10-28 · checked 2026-11-09 15:42 UTC